SPECTRUM: Early global real-world results with aflibercept 8 mg in patients with treatment-naïve diabetic macular edema

Gabriela Grimaldi,[1,2] Aires Lobo,[3] Hassiba Oubraham,[4] Clare Bailey,[5] Paolo Lanzetta,[6,7] Varun Chaudhary,[8] Marion R. Munk,[9,10,11] Tobias Machewitz,[12] Helmut Allmeier,[13] Peter Morgan-Warren,[13] Clemens Lange,[14,15] on behalf of the SPECTRUM study investigators

[1]Istituto Neuroscienze cliniche della Svizzera Italiana, Ospedale Regionale di Lugano, Viganello, Switzerland; [2]Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland; [3]Ophthalmology Department, Moorfields Eye Centre, Bedford Hospital, Bedford, UK; [4]Centre OPHTA-45, Montargis, France; [5]Department of Ophthalmology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK; [6]Department of Medicine–Ophthalmology, University of Udine, Udine, Italy; [7]Istituto Europeo di Microchirurgia Oculare (IEMO), Udine, Italy; [8]Hamilton Regional Eye Institute, St. Joseph's Healthcare Hamilton, McMaster University, Hamilton, ON, Canada; [9]Augenarzt Praxisgemeinschaft Gutblick AG, Pfäffikon, Switzerland; [10]Department of Ophthalmology, University Hospital Bern, Switzerland; [11]Northwestern University, Feinberg School of Medicine, Chicago, IL, USA; [12]Bayer AG, Berlin, Germany; [13]Bayer Consumer Care AG, Basel, Switzerland; [14]Eye Center, Faculty of Medicine, Albert-Ludwig University Freiburg, Freiburg, Germany; [15]Department of Ophthalmology, St. Franziskus Hospital, Münster, Germany

Presented at the ASRS 43rd Annual Meeting, Long Beach, CA, USA, July 30 – August 2, 2025

Disclosures

- **Gabriela Grimaldi:** Consultant and lecturer for AbbVie, Apellis, Bayer, and Roche; and has received grants from Bayer and Roche
- **AL:** Serves on advisory boards for Advanz Pharma, Bayer, GSK, Nordic Pharma, and Roche; and receives honoraria from Bayer and Roche. **HO:** Consultant for AbbVie, Bayer, Novartis, and Roche. **CB**: Received honoraria from Alimera Sciences, Apellis, Bayer, and Roche; and has served on advisory boards for Apellis, Bayer, Boehringer Ingelheim, Janssen, and Roche. **PL:** Consultant for Aerie Pharmaceuticals, Allergan, Annexon, Apellis, Bausch + Lomb, Bayer, Biogen, Boehringer Ingelheim, Eyepoint Pharmaceuticals, Genentech, I-Care, Novartis, Ocular Therapeutix, Outlook Therapeutics, and Roche. **VC:** Consulting fees from EyePoint; receives grants from Bayer, Novartis, and Roche; and serves on the advisory boards of Alcon, Roche, Bayer, Novartis, Apellis, and Boehringer Ingelheim. **MRM:** Consulting fees from AbbVie, Allergan, Apellis, Aviceda Therapeutics, Bayer, Boehringer Ingelheim, Dandelion, EyePoint, Gensight, Isarna Therapeutics, Iveric BioKubota, Lumithera, Novartis, Oculis, Ocuterra, Ocular Therapeutix, RetinAI, Roche, and Zeis. **TM**: Employee of Bayer AG. **HA** and **PM-W:** Employees of Bayer Consumer Care AG. **CL**: Receives honoraria from Apellis, Bayer, Biogen, and Novartis
- The SPECTRUM study (NCT06075147) was sponsored by Bayer Consumer Care AG, Basel, Switzerland
- The sponsor participated in the design and conduct of the study, analysis of the data, and preparation of this presentation
- Medical writing support, under the direction of the authors, was provided by ApotheCom and funded by Bayer Consumer Care AG (Basel, Switzerland), in accordance with Good Publication Practice (GPP) guidance (*Ann Intern Med.* 2022;175:1298–1304)
- Data originally presented at ARVO, Salt Lake City, UT. USA, May 4—8, 2025

SPECTRUM: Global real-world study of aflibercept 8 mg

A **non-interventional country** and **global cohort** study planned in **18 countries**

2 indications, 4 patient cohorts

Treatment-naïve **nAMD** and previously treated **nAMD**
Treatment-naïve **DME** and previously treated **DME**

Primary endpoint: Change in **VA** from **BL to Month 12**

Secondary endpoints include:

- Change in **VA** and **CRT** from BL to Month 6
- Number of **injections** and **visits**, and **safety** through Month 6

To date, **2896** patients enrolled



BL, baseline; CRT, central retinal thickness; DME, diabetic macular edema; nAMD, neovascular age-related macular degeneration; VA, visual acuity.

This presentation describes an overview of the study design, enrollment status, and interim baseline characteristics of the treatment-naïve DME cohort

Enrollment overview

To date, **411** out of **950 (43%)** planned patients have been enrolled in the **treatment-naïve DME** cohort (as of May 30, 2025)



UAE, United Arab Emirates.

Baseline characteristics: Treatment-naïve DME

Baseline characteristics of the first 150 patients enrolled[a]

Mean age: 66.3 ± 11.2 years

Median (min, max) time from DME diagnosis: 0.5 (0.0, 109.2) months

Mean baseline VA: 63.5 ± 15.9 ETDRS letters

Mean baseline CRT: 420 ± 109 µm

Sex



Race[b]



FAS. Percentages may not add up to 100 due to rounding.

[a]Data are mean ± SD unless otherwise indicated. [b]Data on race were collected for Australia, Canada, Germany, Italy, Japan, Portugal, South Korea, Saudi Arabia, Spain, Switzerland, United Arab Emirates, and the UK only.
ETDRS, Early Treatment Diabetic Retinopathy Study; FAS, full analysis set; UK, United Kingdom.

Timeline and planned analyses



SPECTRUM's study design enables analyses on both a **regional** and **global** level, allowing for **rolling interim analyses** of endpoints in each participating country/cohort a year after enrollment is complete

All analyses will be exploratory and descriptive in nature

Q, quarter.

Timeline and planned analyses

First 100 patients with VA assessment after 1st/2nd injection

1-year primary endpoint

2-year secondary endpoint

Month 6 data for the **treatment-naïve DME** cohort will be available in **Q3 2025**

ountry cohort and pooled analysis

SPECTRUM's study design enables analyses on both a **regional** and **global** level, allowing for **rolling interim analyses** of endpoints in each participating country/cohort a year after enrollment is complete

All analyses will be exploratory and descriptive in nature

Q, quarter.

Building on prior RWE experience

AURIGA[1]

A global observational study in patients with treatment-naïve or previously treated DME or macular edema secondary to **RVO** across 11 countries/regions

XTEND[2]

A global observational study in patients with treatment-naïve nAMD across 17 countries



AQUILA[3]

An observational study in patients with treatment-naïve and previously treated nAMD and DME across 4 countries

DRAKO[4]

An observational study in patients with treatment-naïve DME in the UK

Other observational studies of aflibercept 2 mg have included APOLLON (France), PERSEUS (Germany), and PERSEUS-IT (Italy). RVO, retinal vein occlusion; RWE, real-world evidence.

1. Donati S, et al. *Ophthalmol Ther*. 2023;13(1):161–178; 2. Korobelnik JF, et al. *Ophthalmol Ther*. 2024;13(3):725–738;
3. Rodríguez FJ, et al. *Int J retina Vitreous*. 2022;8(1):52; 4. Sivaprasad S, et al. *Eye (Lond)*. 2023;37(12):2527–2534;

Conclusions

This initial report provides insights into the **baseline characteristics (including VA and CRT)** of the **first 150 patients** enrolled in the **treatment-naive DME** cohort

As the **first global real-world study** on aflibercept 8 mg, the **SPECTRUM** study will generate a **wealth of long-term data** on the real-world **effectiveness and safety** of **aflibercept 8 mg** in **nAMD and DME** across geographically and clinically **diverse patient populations**

To date, **411 patients** have been enrolled in the treatment-naïve DME cohort (longest treatment duration of 16 months), and the **first set of evaluations** are underway